Economic Evaluation of Pertuzumab In Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment of Women with HER2-Positive, Locally Advanced, Inflammatory or Early Breast Cancer in Portugal
Abstract
Authors
O Lourenço C Alves P Thuresson F Batel-Marques